Hyper-CVAD方案治疗高度侵袭性非霍奇金淋巴瘤的疗效分析.docVIP

HyperCVAD方案治疗高度非霍奇金淋巴瘤 袁志平1 姚文秀2 吴亚琳1 贾钰铭1 雷开键1 彭生才1 1四川省宜宾市第二人民医院肿瘤科 四川宜宾 644000 2 四川省肿瘤医院肿瘤内科 四川成都610041elE-mail：yuanzhiping9@126.com 通讯作者: 彭生才 E-mail：【摘要】目的：分析HyperCVAD化疗方案治疗高度非霍奇金淋巴瘤的治疗.方法：47例高度恶性NHL患者,T母细胞淋巴瘤39例和Burkitt′s淋巴瘤细胞8例.所有患者接受HyperCVAD化疗方案治疗6～8个周期，鞘内4～16次,早期患者有大肿块或者有残留灶者结果：中位随访时间36个月(12～5月),患者接受了平均.8个周期化疗319个,41例(87.6％)取得完全缓解；26例患者无病生存,中位生存时间34个月（3-51月）,中位复发时间为月（3-2月），1年无病生存率与总生存率分别81.0%和91.4%3年53.2%和5%.高龄,IPI指数高和伴有大肿块,骨髓受侵犯,B症状,晚期患者具有较低的CR率和较差的预后。接受鞘内治疗中枢神经系统复发率%。主要不良反应为骨髓抑制，Ⅲ～Ⅳ度细胞和血小板减少的发生率分别为100％和36.2％。结论：HyperCVAD方案治疗配合鞘内局部放疗是治疗高度侵袭性NHL的有效的方案,具有较高的CR率和3年生存关键词：非霍奇金淋巴瘤高度侵袭性；HyperCVAD方案；鞘内注射；放疗. Therapeutic Efficacy of Hyper-CVAD Regimen on High-aggressive Non-Hodgkin’s Lymphoma Yuan zhi-ping1, Yao wen-xiu2, Wu ya-lin1, Jia yu-ming1, Lei kai-jian1, Peng sheng-cai1 1 Department of oncology, Yibin NO. 2 People Hospital, Sichuan Yibin, 644000, P.R.China 2 Department of medical Oncology，Cancer Hospital, Sichuan province, Sichuan Chengdu 610041, P.R.China [ABSTRACT] OBJECTIVE： to evaluate the efficacy and safety of hyperCVAD regimen in patients with high-aggressive Non-Hodgkin’s Lymphoma. METHODS：orty-seven patients with high-grade NHL，T-cell lymphoblastic lymphoma (39 cases) and Burkett’s lymphoma (8 cases), were treated by Hyper-CVAD regimen for 68 cycles. Ara-C or MTX was alternately given by intrathecal therapy (IT) for 4-16 times according to the danger levels of CNS recurrence. Radiation, with total dose 30-40Gy through routine radioation method, was given in early patients for involved field and in advanced patients for bulky or residual focus. The therapeutic efficacy and adverse effect were observed. RESULTS：(ranged 12-51 months). All these patients received hyperCVAD regimen with a mean of 6.8 cycles (total 319 cycles). 41 patients (87.6%) were complete response (CR) and 26 patients disease-free survival at present. There was median time to failure of 11 months (ranged 3-23 months)，median survival time of 4 months (ranged 3-51 mo